[ad_1]
Past trials with the new vaccine are raising hope, especially in the worsening current situation for the crown. However, there won’t be a quick return to normal, according to the co-founder of vaccine developer Biontech. Ugur Sahin doesn’t expect this until winter 2021.
To achieve this medium-term goal, it is “absolutely essential” to achieve a high vaccination rate against the coronavirus before autumn, he told the British television channel BBC on Sunday.
But he is optimistic that this can be successful. The vaccine developed by Biontech and the US pharmaceutical giant Pfizer is one of the hopes in the fight against the pandemic.
The head of the company, Sahin, announced that the developed vaccine would be available from the end of this year or the beginning of 2021, “if all goes well,” he added. However, he spoke of a “harsh winter” and noted that vaccines developed soon would not have a major impact in the current cold season. Biontech’s goal, however, is to deliver more than 300 million cans by April: “That could have an effect,” he said.
Nearly € 400 million in grants from the federal government
Mainz-based company Biontech and its US partner Pfizer made headlines last week with the announcement that the current clinical trial had found its candidate vaccine more than 90 percent effective.
Biontech was founded in 2008 by Sahin, his wife Özlem Türeci, and Austrian cancer researcher Christoph Huber. Two years ago, the company signed a collaboration agreement with Pfizer, which was expanded to include a search for vaccines in March this year in light of the pandemic. Biontech received a grant from the federal government worth 375 million euros for its research.
